Pharmaffiliates Private Limited - Due diligence report

A 360° intelligence report on Pharmaffilates: trust score, financial health, credit view, compliance, directors, growth and distress signals…

2006-09-29 Panchkula, Haryana Active Unlisted Active Compliant
Share
Connect MCP
PP Pharmaffiliates Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Pharmaffilates — 360° Intelligence Report

Generated from MCA filings & public records
92/100
Trust Score
Low Risk

Pharmaffilates is assessed as Low Risk with a Trust Score of 92/100. Pharmaffilates is an active private limited indian non-government company incorporated in 2006, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 09 Aug 2026 from the latest processed filings. Pharmaffiliates Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
92/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Moderate gearing (D/E 1.42).
  • Profitable - internal accruals available.

Charges position: 5 open (35.30 cr) · 9 satisfied (29.37 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others5 48.0 cr
Yes Bank Limited1 48.0 cr
Axis Bank Limited3 48.0 cr
Canara Bank4 48.0 cr
State Bank Of India1 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
ABHINAV SABARWAL 01234567 Director 01/04/2018 6 yrs Approved
ASHOK KUMAR SABHARWAL 01234567 Director 01/04/2018 6 yrs Approved
MEERA SABHARWAL 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: ASHOK KUMAR SABHARWAL (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
Net margin improved to 38%.
EPFO headcount growing - hiring signal.
Operating for 19+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
5 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence90/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment86/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 5 open charge(s) of 35.30 cr already registered.
  • Compliance record supports lending.
Investor view94/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 6 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
16 Dec 2025
Charge satisfied
Canara Bank
15 Oct 2025
Charge created
Others - 7.00 cr
04 Oct 2025
Charge satisfied
Axis Bank Limited
04 Sep 2025
Charge created
Others - 5.99 cr
31 Aug 2025
Charge created
Others - 7.25 cr
28 Apr 2025
Charge satisfied
Yes Bank Limited
02 Dec 2024
Director appointed
ABHINAV SABARWAL (Additional Director)
01 Dec 2024
Director ceased
ASHOK KUMAR SABHARWAL
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
05 Apr 2023
Charge created
Others - 9.30 cr
28 Sep 2022
Charge created
Yes Bank Limited - 15.96 cr
20 Aug 2021
Charge created
Axis Bank Limited - 30.00 Lakh
10 Sep 2020
Charge created
Axis Bank Limited - 65.00 Lakh
27 Aug 2020
Charge created
Others - 5.76 cr
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Intonation Research Laboratories Private Limited U73200TG2013PTC087978 Hyderabad, Telangana, India
Jasmine Bio Labs Private Limited U74999TG2017PTC115223 Medchal Mandal, Telangana, India
Amgen Technology Private Limited U62099MH2007FTC168485 Mumbai, Maharashtra, India
Premier Research U73100KA2021FTC143738 Bengaluru, Karnataka, India
Cornelius U29130KA2005PTC035967 Bangalore North, Karnataka, India
Promega U51102MH2013PTC248556 Mumbai, Maharashtra, India
Vivo Bio Tech L65993TG1987PLC007163 Hyderabad, Telangana, India
Kala Span Defence Private Limited U29309PN2020PTC194909 Pune, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Pharmaffilates before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Pharmaffilates: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Pharmaffilates - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 92/100, distress signals and MSME payment-delay disclosures - know whether Pharmaffilates pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Pharmaffilates - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Pharmaffilates an active company?

Pharmaffilates has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Pharmaffilates financially healthy?

Pharmaffilates has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Pharmaffilates?

Its overall Trust Score is 92/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Pharmaffilates?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Pharmaffilates have loans or charges against its assets?

5 open charge(s) are registered against its assets, and 9 earlier charge(s) stand satisfied.

Is Pharmaffilates up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Pharmaffilates?

Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.